This article is more than 5 years old. Information may no longer be current.

Xbrane sets sales goals for ranibizumab biosimilar

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Xbrane Biopharma has begun a phase 3 trial of its lead product Xlucane and announced a sales target for the biosimilar, according to a press release.

Xlucane, a ranibizumab (Lucentis, Novartis/Genentech) biosimilar, is being co-developed and commercialized with Stada Arzneimittel AG, and is expected to bring in revenue during the first quarter of 2022, the release said.

The company has set an annual net sales target of 350 million euros after the product launch.

“We strongly believe in the commercial prospects of Xlucane. There is a great need for more cost-efficient products in the ophthalmic VEGFa inhibitor market and I am confident that Xlucane will be received positively by the ophthalmology community and patients,” Xbrane CEO Martin Åmark said.